

# Channing Yu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3942695/publications.pdf>

Version: 2024-02-01

15  
papers

3,792  
citations

623188

14  
h-index

940134

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

4709  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Critical Role for Eosinophils in Allergic Airways Remodeling. <i>Science</i> , 2004, 305, 1776-1779.	6.0	807
2	FOG, a Multitype Zinc Finger Protein, Acts as a Cofactor for Transcription Factor GATA-1 in Erythroid and Megakaryocytic Differentiation. <i>Cell</i> , 1997, 90, 109-119.	13.5	685
3	Targeted Deletion of a High-Affinity GATA-binding Site in the GATA-1 Promoter Leads to Selective Loss of the Eosinophil Lineage In Vivo. <i>Journal of Experimental Medicine</i> , 2002, 195, 1387-1395.	4.2	538
4	GATA-1 and Erythropoietin Cooperate to Promote Erythroid Cell Survival by Regulating bcl-xL Expression. <i>Blood</i> , 1999, 94, 87-96.	0.6	338
5	PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. <i>Blood</i> , 2000, 96, 2641-2648.	0.6	335
6	Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. <i>Nature Genetics</i> , 2005, 37, 613-619.	9.4	262
7	High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. <i>Nature Biotechnology</i> , 2016, 34, 419-423.	9.4	245
8	X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. <i>Blood</i> , 2002, 100, 2040-2045.	0.6	194
9	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2022, 12, 74-89.	7.7	133
10	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2019, 120, 612-620.	2.9	109
11	Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. <i>Nature Genetics</i> , 2021, 53, 1196-1206.	9.4	47
12	PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. <i>Blood</i> , 2000, 96, 2641-2648.	0.6	35
13	EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd. <i>Cancer Research</i> , 2022, 82, 130-141.	0.4	29
14	Structural mechanism of synergistic activation of Aurora kinase B/C by phosphorylated INCENP. <i>Nature Communications</i> , 2019, 10, 3166.	5.8	21
15	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , 2020, 26, 6122-6131.	3.2	9